spacer
home > ict > summer 2021 > top 10 factors to design and deploy a decentralised clinical trial
PUBLICATIONS
International Clinical Trials

Top 10 Factors to Design and Deploy a Decentralised Clinical Trial


The evolution of clinical research has been shaped by multiple factors that reflect the present need to create novel trial designs with optimised efficiencies. Modern trial design and deployment embraces individuals early and follows participant-centric approaches. Many trial-related activities are brought to participants in the environments where they live, contrasting with traditional trials in which participants frequently travel to distant sites. However, the main goal of modern and traditional trials is the same, both are designed to evaluate the safety and efficacy of new medical products. In both cases, this is accomplished with the same level of regulatory and legal expectation of maintaining participants’ safety and privacy, while ensuring data quality and integrity. Modern clinical trials achieve this with a greater level of convenience, access for diverse races and ethnicities, and often a higher level of engagement and retention of participants.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Dr Isaac Rodriguez-Chavez is Senior Vice President, Scientific and Clinical Affairs and decentralised clinical trials at ICON. He is a biomedical leader with expertise in virology, microbiology, immunology, vaccinology, and viral oncology. His expertise spans basic, translational, preclinical, and clinical research (Phase I-IV global trials). He also has expertise in digital health technologies, clinical research development and operations, regulatory affairs, approval or licensure of medical products, and quality control and quality assurance. Overall, Isaac has more than 32 years of work experience in several national and international organisations, including the FDA, NIH, and industry and non-profit research organisations. He has a BSc in Biology (Venezuela), MSc in Microbiology (Venezuela), MHSc in Clinical Research (Duke School of Medicine, US), and a PhD in Virology and Immunology (University of Delaware, US). Isaac completed two postdoctoral trainings in viral immunology and viral oncology at the National Institute on Aging and the National Cancer Institute at NIH, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

va-Q-tec: Global specialist for TempChain transport solutions and energy efficiency continues on successful track in the first half of 2022

Würzburg, 11 August, 2022. va-Q-tec AG (ISIN DE0006636681 / WKN 663668), a pioneer in highly efficient products and solutions in the thermal insulation (so-called super insulation) and temperature-managed supply chains (so-called TempChain logistics) area, continued on its past quarters’ profitable growth path in the first half of 2022. Revenue growth in the first half of 2022 was very gratifying overall despite the challenging macroeconomic environment, thanks to the highly sought-after product and service portfolio.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement